Skip to main content
Equibles

Grant Pickering

CEO

Vaxcyte, Inc. (PCVX)

Board Member

Vaxcyte, Inc. (PCVX)

Board Member

LeonaBio, Inc. (LONA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Vaxcyte, Inc. publishes a filing, an earnings call transcript or a press release.

Get PCVX alerts

About Grant Pickering

Grant Pickering is recorded as CEO and Board Member at Vaxcyte, Inc. (PCVX) and Board Member at LeonaBio, Inc. (LONA) since January 1, 2022. The newest filing on record that lists Grant Pickering as CEO and Board Member at Vaxcyte, Inc. (PCVX) is dated April 23, 2026. The newest filing on record that lists Grant Pickering as Board Member at LeonaBio, Inc. (LONA) is dated May 11, 2026. The proxy statement of Vaxcyte, Inc. reports total compensation of $14,458,937 for Grant Pickering in fiscal 2025, including a base salary of $800,000. Disclosed compensation is on record for 6 fiscal years. Grant Pickering has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for Vaxcyte, Inc. on September 8, 2026. Vaxcyte, Inc. is classified in the Biotechnology industry within the Healthcare sector. LeonaBio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vaxcyte, Inc. includes Andrew Guggenhime (CFO), Jim Wassil (COO), Mikhail Eydelman (General Counsel) and 7 others.

Grant Pickering on recent calls

“And if you don't know VaxCite, we are a vaccine platform company. We have a cell-free protein synthesis platform that allows us to do two key things that are out of reach of other technologies.”
CEO, Wells Fargo 21st Annual Healthcare Conference ·
“As we close out 2025 and look forward to multiple clinical readouts beginning later this year, I'm proud of the progress we made across the company, particularly within our pneumococcal conjugate vaccine, or PCV, franchise.”
CEO, Vaxcyte, Inc. Q4 FY2025 Earnings Call ·
“Vaccines are one of the most powerful innovations in modern medicine, transforming public health by preventing disease, reducing hospitalizations, and saving millions of lives every year.”
CEO, Vaxcyte, Inc. Q4 FY2024 Earnings Call ·
“2023 was another remarkable year for Vaxcyte, officially marking our 10th year of thoughtful and methodical research and development by the entire Vaxcyte team and our partners.”
CEO, Vaxcyte, Inc. Q4 FY2023 Earnings Call ·
“Thank you, Andrew, and to all of you on the call and webcast, thanks for joining us today. 2022 is a landmark year for Vaxcyte.”
CEO, Vaxcyte, Inc. Q4 FY2022 Earnings Call ·

Affiliation history

Company network

LeonaBio, Inc.

LONA

Current role

Biotechnology · Healthcare

Board Member

2022-01-01–present

Leadership on record at Vaxcyte, Inc.

Leadership on record at LeonaBio, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Vaxcyte, Inc. (PCVX) $800,000 $14,458,937
2024 Vaxcyte, Inc. (PCVX) $700,000 $39,639,512
2023 Vaxcyte, Inc. (PCVX) $640,000 $12,135,684
2022 Vaxcyte, Inc. (PCVX) $600,666 $13,661,941
2021 Vaxcyte, Inc. (PCVX) $574,800 $5,291,474
2020 Vaxcyte, Inc. (PCVX) $481,042 $3,374,620

Recent activity